Wedbush Maintains Outperform on Pyxis Oncology, Raises Price Target to $8
Wedbush analyst Robert Driscoll maintains Pyxis Oncology (NASDAQ:PYXS) with a Outperform and raises the price target from $6 to $8.
A stock expert thinks Pyxis Oncology is a good company and raised their guess for where the stock might go. When experts raise their price guesses, it usually means they see better things ahead for the business.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.